

El Salvador

Tuberculosis profile

Population 2015

6.1 million

Estimates of TB burden*, 2015	Number (thousands)	Rate (per 100 000 population)
Mortality (excludes HIV+TB)	0.12 (0.085–0.15)	1.9 (1.4–2.5)
Mortality (HIV+TB only)	0.024 (<0.01–0.12)	0.39 (0–1.9)
Incidence (includes HIV+TB)	2.7 (2.4–2.9)	43 (40–47)
Incidence (HIV+TB only)	0.21 (0.19–0.23)	3.5 (3.2–3.8)
Incidence (MDR/RR-TB)**	0.04 (0.014–0.067)	0.65 (0.23–1.1)

Estimated TB incidence by age and sex (thousands)*, 2015

	0-14 years	> 14 years	Total
Females	0.15 (0.11–0.2)	0.74 (0.5–0.98)	0.89 (0.61–1.2)
Males	0.12 (0.089–0.16)	1.6 (1.3–2)	1.8 (1.4–2.1)
Total	0.28 (0.22–0.33)	2.4 (2.3–2.5)	2.7 (2.4–2.9)

TB case notifications, 2015

Total cases notified	2 461
Total new and relapse	2 452
- % tested with rapid diagnostics at time of diagnosis	15%
- % with known HIV status	97%
- % pulmonary	86%
- % bacteriologically confirmed among pulmonary	90%

Universal health coverage and social protection

TB treatment coverage (notified/estimated incidence), 2015	92% (85–100)
TB patients facing catastrophic total costs	
TB case fatality ratio (estimated mortality/estimated incidence), 2015	0.05 (0.03–0.08)

TB/HIV care in new and relapse TB patients, 2015

	Number	(%)
Patients with known HIV-status who are HIV-positive	182	8%
- on antiretroviral therapy	152	84%

Drug-resistant TB care, 2015	New cases	Previously treated cases	Total number***
Estimated MDR/RR-TB cases among notified pulmonary TB cases			30 (10–50)
Estimated % of TB cases with MDR/RR-TB	1.1% (0.17–2.1)	4.1% (1.3–9.2)	
% notified tested for rifampicin resistance	49%	47%	1 194
MDR/RR-TB cases tested for resistance to second-line drugs			0
Laboratory-confirmed cases		MDR/RR-TB: 25, XDR-TB: 0	
Patients started on treatment ****		MDR/RR-TB: 22, XDR-TB: 0	

Treatment success rate and cohort size	Success	Cohort
New and relapse cases registered in 2014	91%	2 206
Previously treated cases, excluding relapse, registered in 2014	43%	14
HIV-positive TB cases, all types, registered in 2014	75%	203
MDR/RR-TB cases started on second-line treatment in 2013	90%	10
XDR-TB cases started on second-line treatment in 2013		0

TB preventive treatment, 2015

% of HIV-positive people (newly enrolled in care) on preventive treatment	39%
% of children (aged < 5) household contacts of bacteriologically-confirmed TB cases on preventive treatment	

TB financing, 2016

National TB budget (US\$ millions)	5.8
Funding source: 29% domestic, 71% international, 0% unfunded	


* Ranges represent uncertainty intervals

** MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin

*** Includes cases with unknown previous TB treatment history


**** Includes patients diagnosed before 2015 and patients who were not laboratory-confirmed

(Rate per 100 000 population per year)



Mortality (excludes HIV+TB)

(Rate per 100 000 population per year)




Incidence
Notified (new and relapse)
Incidence (HIV+TB only)

Notified cases by age group and sex, 2015



Treatment success rate (%)



New and relapse
Retreatment, excluding relapse
HIV-positive MDR/RR-TB XDR-TB

Total budget (US\$ millions)

